These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
37. Linezolid and quinupristin/dalfopristin: novel antibiotics for gram-positive infections of the skin. Schweiger ES; Scheinfeld NS; Tischler HR; Weinberg JM J Drugs Dermatol; 2003 Aug; 2(4):378-83. PubMed ID: 12884459 [TBL] [Abstract][Full Text] [Related]
38. Efficacy of quinupristin/dalfopristin versus vancomycin, alone or in combination with rifampicin, against methicillin-resistant Staphylococcus aureus in a rabbit arthritis model. Hamel A; Caillon J; Jacqueline C; Batard E; Potel G Int J Antimicrob Agents; 2008 Feb; 31(2):158-60. PubMed ID: 18006281 [TBL] [Abstract][Full Text] [Related]
39. Quinupristin/dalfopristin and linezolid: spectrum of activity and potential roles in therapy--a status report. Batts DH; Lavin BS; Eliopoulos GM Curr Clin Top Infect Dis; 2001; 21():227-51. PubMed ID: 11572153 [No Abstract] [Full Text] [Related]
40. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. Nichols RL; Graham DR; Barriere SL; Rodgers A; Wilson SE; Zervos M; Dunn DL; Kreter B J Antimicrob Chemother; 1999 Aug; 44(2):263-73. PubMed ID: 10473234 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]